Afinitor, Afinitor Disperz, Zortress, Votubia (everolimus) is a small molecule pharmaceutical. Everolimus was first approved as Afinitor on 2009-03-30. It has been approved in Europe to treat breast neoplasms, pancreatic neoplasms, renal cell carcinoma, and tuberous sclerosis. The pharmaceutical is active against serine/threonine-protein kinase mTOR. In addition, it is known to target Cytochrome P450. Afinitor's patents are valid until 2028-07-01 (FDA).
|Trade Name||Afinitor, Votubia|
|Indication||breast neoplasms, pancreatic neoplasms, renal cell carcinoma, tuberous sclerosis|
|Drug Class||Immunosuppressives: immunosuppressant, rapamycin derivatives|